FOSUN HEALTH Logo

Pancreatic Cancer Diagnosis

catalogue

Pancreatic Cancer Diagnosis

Pancreatic Cancer Diagnosis

Diagnosis of pancreatic cancer is a sequence of questions, and the order matters: is there a mass, is it removable, and what is it made of. The right scan answers the first two; a needle answers the third.

CT first, and why the protocol matters

The first-line test is a multiphase contrast-enhanced CT of the pancreas, and the word protocol is what makes it useful. A routine abdominal scan taken in one phase will show a mass, but it will not reliably show whether that mass is separable from the superior mesenteric artery — and that single question decides whether surgery is on the table.

A pancreatic protocol study images the gland in thin slices during the phases when arterial and venous anatomy are clearest, and it is reported with the vessels specifically described. When a CT is equivocal, or when a patient cannot have iodinated contrast, MRI with MRCP is the alternative: it characterises small liver lesions better and shows the ducts without contrast, which is useful when a stent is already in place.

  • What CT answers — is there a pancreatic mass; does it touch, abut or encase the artery; is the vein involved; are there liver or peritoneal deposits; is the bile duct dilated.
  • What MRI adds — indeterminate liver lesions, small cystic lesions, and ductal anatomy without contrast.
  • What neither can do — tell you the cell type. A scan describes anatomy, not biology.

This is why sending pictures rather than a report matters so much for a second opinion. Resectability is decided by looking at the images, and a report that says "mass in the pancreas with vascular contact" does not contain the information a surgeon needs to say whether it is operable.

Endoscopic ultrasound and the tissue diagnosis

Endoscopic ultrasound places a small ultrasound probe in the stomach and duodenum, a few millimetres from the pancreas, and it can do two things at once: describe the tumour and the nodes in detail, and pass a needle through the gut wall to obtain cells or tissue. That combination is why it is the standard route to a diagnosis.

  • Fine-needle aspiration gives cells for cytology and is the usual choice when a diagnosis needs to be confirmed before chemotherapy.
  • Fine-needle biopsy takes a core of tissue, which allows architecture to be assessed and yields more material for molecular testing — relevant when a KRAS variant, a BRCA alteration or mismatch repair status will influence treatment.
  • Timing — if the tumour is going straight to surgery, some centres operate without a pre-operative needle, because the diagnosis will be made on the resected specimen. If chemotherapy is planned first, a tissue diagnosis is required before it starts.

Two practical caveats are worth knowing. A negative biopsy does not exclude cancer, because the needle can miss; the imaging findings then carry the decision. And if the tumour is unresectable, the tissue diagnosis is not optional — systemic treatment should not begin on the basis of imaging alone.

CA19-9: what the marker can and cannot do

CA19-9 is a carbohydrate antigen shed by pancreatic and biliary cells. It is measured from a blood sample, it is cheap, and it is the marker most often ordered — and it is also the most often misunderstood.

  • It can be normal in cancer. People who are Lewis-antigen negative — roughly one in twenty — do not produce it at all, however advanced the tumour.
  • It rises without cancer. Any obstruction of the bile duct raises it: gallstones, cholangitis, and a stent that has just been placed. A level taken during jaundice has to be interpreted with that in mind.
  • It is not a screening test. A normal value does not exclude the disease, and it is not recommended for screening people without symptoms.
  • Its trend is more useful than its value. A baseline before treatment, then measurements afterwards, tell you whether the treatment is working; a single number tells you very little.

The correct use of CA19-9 in pancreatic cancer is therefore as a baseline and a trend marker: measured before surgery or chemotherapy, repeated at defined points, and read together with imaging. If the level falls while on treatment and rises later, that is a signal to restage even before symptoms return.

Staging: what the tests are looking for

Staging pancreatic cancer means answering four questions, and each is answered by a different part of the work-up:

  • How deep is the tumour, and does it reach beyond the gland? Answered by the pancreatic protocol CT, and refined by endoscopic ultrasound for small tumours.
  • Are the regional nodes involved? Answered by CT and EUS; node staging is less accurate than in some other cancers, which is one reason surgery is not abandoned on the basis of a single enlarged node.
  • Is there distant spread? The liver is the commonest site, then the peritoneum and the lungs. CT covers most of this; PET-CT is used when the CT findings are equivocal or when a metastatic deposit would change the plan.
  • Is there occult peritoneal disease? Small deposits on the peritoneum can be invisible on any scan. Staging laparoscopy — a short keyhole look before committing to an operation — finds them in a proportion of patients with otherwise resectable disease and saves an unnecessary laparotomy.

The output of staging is not just a stage number. It is the resectability category, and it should be written down explicitly, because that is what the treatment plan is built on and what makes a second opinion meaningful.

How resectability is judged

Resectability in pancreatic cancer is a statement about the plane between the tumour and the vessels, and it is expressed in four categories rather than as a stage:

  • Resectable — a clear fat plane between the tumour and the superior mesenteric artery and coeliac axis, with the portal vein clear or only touching it. Surgery first, then chemotherapy.
  • Borderline resectable — short-segment abutment or narrowing of the portal or superior mesenteric vein that can be resected and reconstructed, or abutment of an artery without encasement. Chemotherapy first, then re-image and reconsider surgery.
  • Locally advanced — the tumour encircles a major artery, so a margin-negative removal is not achievable. Systemic treatment with or without radiotherapy, and the possibility of surgery is reviewed if the tumour regresses away from the artery.
  • Metastatic — spread beyond the pancreas. Surgery on the primary tumour does not improve the outcome in this situation, and treatment is systemic.

Because the judgement is made from images and is not always clear-cut, the most useful thing a patient can do is have the CT reviewed where pancreatic resections are performed routinely. Borderline and locally advanced are decided by millimetres and by interpretation, and the treatment pathway that follows from one or the other is entirely different.

Arranging the work-up from abroad

Nothing in the pancreatic work-up needs to be repeated unnecessarily, and most of it can be reviewed remotely before any travel is considered. What matters is that the right material is sent, because a pancreatic diagnosis cannot be reconstructed from a summary letter.

  • The CT on disc, in DICOM format rather than as images in a PDF, with the report if available. This is the single most important item.
  • The MRI or MRCP if one was done, and any PET-CT.
  • The endoscopy and cytology reports, including the exact wording of the cytology conclusion — "atypical", "suspicious" and "positive for adenocarcinoma" mean different things.
  • Blood results, including CA19-9, bilirubin, liver enzymes and HbA1c, with the dates they were taken.
  • A list of current medication, particularly anticoagulants, diabetes treatment and any stents that have been placed.

From those items the team can usually state which category the tumour falls into, whether treatment should begin with chemotherapy or with surgery, and what further tests — if any — are worth doing in China. Where an up-to-date pancreatic protocol CT is genuinely needed, it can be arranged quickly, but it should be a decision made with the images already reviewed rather than a routine first step.

Frequently Asked Questions

Can a CT scan miss pancreatic cancer?

It can, and small tumours are the usual reason. A contrast-enhanced pancreatic protocol CT detects the great majority of pancreatic adenocarcinomas above about two centimetres, but small tumours — particularly those that do not deform the gland contour — can be subtle. If clinical suspicion is high and the CT is normal, endoscopic ultrasound is the next step, because it looks at the gland from a few millimetres away and can sample anything it finds.

Do I need a biopsy before starting chemotherapy?

Yes, in almost all cases. Chemotherapy is given for months and carries real side effects, so it should not be started on imaging alone — and occasionally the imaging turns out to be wrong, with the mass proving to be a neuroendocrine tumour, a lymphoma or a focal area of autoimmune pancreatitis, each of which is treated differently. The exception is a patient going straight to surgery, where the diagnosis is made on the resected specimen.

What is staging laparoscopy and do I need it?

It is a short keyhole operation that looks at the surface of the peritoneum and the liver before committing to a full pancreatic resection. It exists because small peritoneal deposits can be invisible on CT and PET-CT, and finding them during a planned resection means an operation that cannot achieve its aim. It is most useful in tumours of the body and tail and in those with a high CA19-9, where the chance of occult spread is greater.

How long does it take to complete the tests?

For a patient already in hospital, staging is usually complete within a week: a pancreatic protocol CT, blood work including CA19-9, and endoscopic ultrasound with a needle. Where biliary drainage is needed first, or where a PET-CT or laparoscopy is added, it can take somewhat longer. The rate-limiting step is almost always access to the imaging and the endoscopy, not the tests themselves — which is one reason a review of existing films is worth doing before any of it is repeated.

Patient Stories

Stories from our pancreatic cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Not sure whether the tumour is operable?

Send the CT on disc, the endoscopy and cytology reports and the CA19-9 value. Our hepato-pancreato-biliary team will review the images and return a written assessment within 48 hours — including the resectability category and whether treatment should start with chemotherapy or with surgery.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*